Research Topic · Peer-Reviewed

Protease Inhibitors

Protease inhibitors are agents that block the catalytic activity of proteases, the enzymes that cleave peptide bonds in proteins. In therapeutics they are most prominent as antiviral drugs that target virally encoded proteases essential for the maturation of infectious particles, as in the treatment of human immunod…

Curated from this journal's research 📚 12 peer-reviewed articles cited Cited 18× across the literature 🔖 ISSN 2328-0182 🗓 Reviewed July 2026

Overview

Protease inhibitors are agents that block the catalytic activity of proteases, the enzymes that cleave peptide bonds in proteins. In therapeutics they are most prominent as antiviral drugs that target virally encoded proteases essential for the maturation of infectious particles, as in the treatment of human immunodeficiency virus (HIV) and hepatitis C virus (HCV), where inhibiting proteolytic processing of viral polyproteins halts the production of mature, replication-competent virions. By design they bind the enzyme active site and prevent substrate cleavage, and their use is shaped by considerations of potency, resistance, and combination with other antiviral classes. Research in this area examines protease-inhibitor-containing antiretroviral and 2-drug regimens for HIV management, treatment completion and resistance patterns in HCV and HIV populations, and the broader pharmacology of enzyme-targeted drugs, alongside proteomic methods used to study protease substrates and enzyme regulation. Related strands include drug-resistance characterisation, adherence in resource-limited settings, and structure-activity work on related anti-infective chemotypes. The class matters because protease-targeted therapy transformed the management of chronic viral infection and continues to inform antiviral and anticancer drug development. The journal publishes peer-reviewed research on antiviral pharmacology, enzyme-targeted agents, and the clinical management of infections treated with these drugs.

Research published in this journal

12 peer-reviewed articles, ranked by relevance. Each links to its DOI.

2020

The Novel Coronavirus 2019 (COVID-19): A Narrative Review

Rezapour BarataliCorresponding author
Department of Public Health, Faculty of Health, Assistant Professor, PhD in Health education and promotion, Urmia University of Medical Sciences, Urmia, Iran
Exact topic International Journal of Coronaviruses Cited by 2 doi:10.14302/issn.2692-1537.ijcv-20-3373
2013

Quantitative Proteomics Using 15N SILAC Mouse

I. Chen EmilyCorresponding author
Stony Brook University, Proteomics Center, School Of Medicine, NY
Exact topic Proteomics and Genomics Research Cited by 4 doi:10.14302/issn.2326-0793.jpgr-13-252
2013

Pattern of Use of Highly Active Antiretroviral Therapy Regimens and Pattern of Occurrence of Adverse Drug Reactions in an Indian Human Immunodeficiency Virus Positive Patients

Rajesh RadhakrishnanCorresponding author
Radhakrishnan Rajesh M.Pharm, Asst Professor (Senior Grade), Department of Pharmacy Practice, Manipal College of pharmaceutical Sciences, Manipal University, Manipal- 576 104, Karnataka, India.
Exact topic Clinical Research In HIV AIDS And Prevention Cited by 1 doi:10.14302/issn.2324-7339.jcrhap-12-174

How this research is being cited

The 12 articles above have been cited 18 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Protease Inhibitors, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Advanced Pharmaceutical Science And Technology (ISSN 2328-0182).

Journal editorial board
natalia malara · Italy Saba Khalilpour · Italy Haseeb Khan · United States

This page summarises published research for orientation; it is not medical or professional advice.